Scarica l'app Stockscreener
4.895
4.11%
-0.21
Dopo l'orario di chiusura:
4.90
0.005
+0.10%
Precedente Chiudi:
$5.105
Aprire:
$5.21
Volume 24 ore:
923.99K
Relative Volume:
1.10
Capitalizzazione di mercato:
$268.71M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-2.8964
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
-15.89%
1M Prestazione:
-22.42%
6M Prestazione:
-37.88%
1 anno Prestazione:
-19.49%
Intervallo 1D:
$4.83
$5.2188
Intervallo di 1 settimana:
$4.83
$6.0395
Portata 52W:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.895 | 321.69M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics: Assessing the Impact of BofA's Downgrade on a Promising Biotech - AInvest
Candel Therapeutics Falls After Downgrade From BofA Securities - MarketScreener
Erasca, Candle, Xencor drop as BofA downgrades (ERAS:NASDAQ) - Seeking Alpha
What does recent volatility data suggest for Candel Therapeutics Inc.Forecast Cut & AI Enhanced Trade Execution Alerts - Newser
Candel Therapeutics Downgraded to Neutral by B of A Securities - AInvest
Pattern recognition hints at Candel Therapeutics Inc. upside - Newser
Price action breakdown for Candel Therapeutics Inc.July 2025 Selloffs & Precise Swing Trade Alerts - Newser
What momentum shifts mean for Candel Therapeutics Inc.July 2025 Weekly Recap & Trade Opportunity Analysis - Newser
BofA Securities Downgrades Candel Therapeutics to Neutral From Buy - MarketScreener
Multi asset correlation models including Candel Therapeutics Inc.2025 Market Trends & Safe Swing Trade Setups - Newser
Will Candel Therapeutics Inc. benefit from macro trendsJobs Report & Smart Swing Trading Alerts - Newser
Chart based analysis of Candel Therapeutics Inc. trends2025 Analyst Calls & Capital Protection Trading Alerts - Newser
How to track smart money flows in Candel Therapeutics Inc.2025 Trading Volume Trends & Fast Gain Stock Trading Tips - Newser
How high can Candel Therapeutics Inc. stock goWeekly Profit Recap & Pattern Based Trade Signal System - Newser
How hedge fund analytics apply to Candel Therapeutics Inc. stockJuly 2025 Opening Moves & Consistent Income Trade Ideas - Newser
Candel Therapeutics shares rise 1.71% after-hours after appointing renowned immunotherapy expert Carl H. June to its Research Advisory Board. - AInvest
Rally Mode: Is Candel Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Macro Moves & AI Powered Market Entry Strategies - khodrobank.com
Small Cap Stocks Gain Traction: MustGrow Biologics, Ocean Power Technologies, Medicus Pharma, Candel Therapeutics, Digi Power X, and G Mining Ventures Lead the Way - AInvest
Candel Therapeutics Inc. stock daily chart insightsMarket Activity Summary & Breakout Confirmation Alerts - Newser
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board - The Manila Times
FDA-Approved CAR-T Pioneer Carl June Joins Candel Therapeutics to Guide Cancer Immunotherapy Development - Stock Titan
Live market analysis of Candel Therapeutics Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - Newser
Will Candel Therapeutics Inc. face regulatory challengesJuly 2025 Short Interest & Stepwise Trade Execution Plans - khodrobank.com
Published on: 2025-09-02 07:27:55 - beatles.ru
Using data models to predict Candel Therapeutics Inc. stock movement2025 Trade Ideas & High Win Rate Trade Tips - Newser
Is Candel Therapeutics Inc. a play on infrastructure spendingJuly 2025 Breakouts & Real-Time Volume Spike Alerts - khodrobank.com
Is Candel Therapeutics Inc. stock entering bullish territory2025 Dividend Review & Technical Buy Zone Confirmation - Newser
Can Candel Therapeutics Inc. expand its profit margins2025 Investor Takeaways & Low Drawdown Momentum Trade Ideas - khodrobank.com
Advanced analytics toolkit walkthrough for Candel Therapeutics Inc.2025 Trading Recap & Daily Entry Point Trade Alerts - Newser
Multi asset correlation models including Candel Therapeutics IncJuly 2025 Weekly Recap & Community Supported Trade Ideas - Newser
What indicators show strength in Candel Therapeutics Inc.Weekly Trend Report & Verified Technical Trade Signals - Newser
Trend Dashboard Flags Candel Therapeutics Inc. As Potential Swing TradeJuly 2025 Movers & Long-Term Capital Growth Strategies - beatles.ru
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Candel Therapeutics Inc Azioni (CADL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):